The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β
Abstract
Objective: T‐helper 1 (Th1) and Th17 lymphocytes are involved in experimental autoimmune encephalomyelitis, the model of multiple sclerosis (MS). We characterized the Th1/Th17 cell populations in peripheral blood (PB), their interferon (IFN) receptor expression sensitivity to IFN‐β in MS patients. Methods: In 30 untreated patients with active MS (AMS) and 32 with inactive MS (IMS), and in 22 healthy subjects, we measured intracellular cytokine expression, interleukin‐17–producing myelin basic protein–stimulated PB lymphocytes, surface IFN type I receptor chain1 (IFN‐αR1) expression, IFN‐β‐dependent signal transducer and activator of transcription 1 (STAT1) phosphorylation, and apoptosis of anti‐CD3 monoclonal antibody–stimulated PB lymphocytes. Results: Th17 cell percentage increased around sevenfold in AMS compared with IMS or healthy subjects, but there was no change in Th1 cells. Th17 cells in AMS were myelin basic protein specific. The longitudinal follow‐up of 18 MS patients shifting between AMS and IMS showed that the percentage of Th17 but not Th1 cells always increased in AMS. IFN‐αR1 expression, IFN‐β–induced STAT1 activation, and apoptosis were significantly greater in Th17 than Th1 cells. IFN‐αR1 expression and IFN‐β–dependent STAT1 activation progressively increased in vitro with a highly significant positive correlation only in developing Th17 but not in Th0 or Th1 cells. Interpretation: Evidence that an expansion of peripheral Th17 cells, a Th subset that can infiltrate brain parenchyma and damage cells, is associated with disease activity in MS. The greater IFN‐αR1 level expressed by Th17 compared with Th1 cells might make them a selective target for IFN‐β therapy. Ann Neurol 2009;65:499–509
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., & Riccardi, C. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90198-o · Cited by 4,579
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Phenotypic and functional features of human Th17 cells
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070663 · Cited by 1,861
Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
TH-17 cells in the circle of immunity and autoimmunity
Bettelli, E., Oukka, M., & Kuchroo, V. K. (2007) · Nature Immunology · doi:10.1038/ni0407-345 · Cited by 1,517
Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J., Newcombe, J., Esiri, M. M., & Fugger, L. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070690 · Cited by 1,187
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1
Amadi-Obi, A., Yu, C.-R., Liu, X., Mahdi, R. M., Clarke, G. L., Nussenblatt, R. B., Gery, I., Lee, Y. S., & Egwuagu, C. E. (2007) · Nature Medicine · doi:10.1038/nm1585 · Cited by 865
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
Matusevicius, D., Kivisäkk, P., He, B., Kostulas, N., Özenci, V, Fredrikson, S., & Link, H. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500206 · Cited by 751
Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.
Selmaj, K., Raine, C. S., Cannella, B., & Brosnan, C. F. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115102 · Cited by 738
Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor
Cosmi, L., De Palma, R., Santarlasci, V., Maggi, L., Capone, M., Frosali, F., Rodolico, G., Querci, V., Abbate, G., Angeli, R., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080397 · Cited by 706
Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., & Mescher, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4465 · Cited by 630
Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells
Stromnes, I. M., Cerretti, L. M., Liggitt, D., Harris, R. A., & Goverman, J. M. (2008) · Nature Medicine · doi:10.1038/nm1715 · Cited by 630
Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., & Zaffaroni, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08430-1 · Cited by 547
Self-citationBrück, W., Bitsch, A., Kolenda, H., Brück, Y., Stiefel, M., & Lassmann, H. (1997) · Annals of Neurology · doi:10.1002/ana.410420515 · Cited by 519
Prinz, M., Schmidt, H., Mildner, A., Knobeloch, K.-P., Hanisch, U.-K., Raasch, J., Merkler, D., Detje, C., Gutcher, I., Mages, J., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.011 · Cited by 387
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice
Guo, B., Chang, E. Y., & Cheng, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33342 · Cited by 371
McFarland, H. F., Frank, J. A., Albert, P. S., Smith, M. E., Martin, R., Harris, J. O., Patronas, N., Maloni, H., & McFarlin, D. E. (1992) · Annals of Neurology · doi:10.1002/ana.410320609 · Cited by 346
Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
Wee Yong, V., Chabot, S., Stuve, O., & Williams, G. (1998) · Neurology · doi:10.1212/wnl.51.3.682 · Cited by 344
The Receptor of the Type I Interferon Family
Uzé, G., Schreiber, G., Piehler, J., & Pellegrini, S. (2007) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-71329-6_5 · Cited by 260
Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C., De Jager, P., & Baecher‐Allan, C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00240.x · Cited by 260
Multiple sclerosis: Involvement of interferons in lesion pathogenesis
Traugott, U., & Lebon, P. (1988) · Annals of Neurology · doi:10.1002/ana.410240211 · Cited by 186
Steinman, L. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072066 · Cited by 175
The cytokine storm in multiple sclerosis
Link, H. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400104 · Cited by 163
Heremans, H., Dillen, C., Groenen, M., Martens, E., & Billiau, A. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261019 · Cited by 148
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases
Dhib-Jalbut, S. S., Arnold, D. L., Cleveland, D. W., Fisher, M., Friedlander, R. M., Mouradian, M. M., Przedborski, S., Trapp, B. D., Wyss‐Coray, T., & Yong, V. W. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.03.027 · Cited by 91
What do we know about the mechanism of action of disease-modifying treatments in MS?
Hartung, H., Bar‐Or, A., & Zoukos, Y. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1504-y · Cited by 75
Novelli, F., D’Elios, M. M., Bernabei, P., Ozmen, L., Rigamonti, L., Almerigogna, F., Forni, G., & Prete, G. D. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.206 · Cited by 75
Self-citationDown-Modulation of Responses to Type I IFN Upon T Cell Activation
Dondi, E., Rogge, L., Lutfalla, G., Uzé, G., & Pellegrini, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.749 · Cited by 69
IFNγR2 trafficking tunes IFNγ–STAT1 signaling in T lymphocytes
Regis, G., Conti, L., Boselli, D., & Novelli, F. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.12.002 · Cited by 48
Self-citationImmunological patterns identifying disease course and evolution in multiple sclerosis patients
Furlan, R., Rovaris, M., Boneschi, F. M., Khademi, M., Bergami, A., Gironi, M., Deleidi, M., Agosta, F., Franciotta, D. M., Scarpini, E. A., et al. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.012 · Cited by 40
In the absence of IGF-1 signaling, IFN-γ suppresses human malignant T-cell growth
Conti, L., Regis, G., Longo, A., Bernabei, P., Chiarle, R., Giovarelli, M., & Novelli, F. (2006) · Blood · doi:10.1182/blood-2006-07-034231 · Cited by 29
Self-citationHong, J., Zang, Y. C. Q., Li, S., Rivera, V. M., & Zhang, J. Z. (2004) · European Journal of Immunology · doi:10.1002/eji.200324790 · Cited by 21
Cited by
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N., & Mills, K. H. G. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04143.x · Cited by 945
Bifidobacteria-mediated immune system imprinting early in life
Henrick, B. M., Rodriguez, L., Lakshmikanth, T., Pou, C., Henckel, E., Arzoomand, A., Olin, A., Wang, J., Mikes, J., Tan, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.030 · Cited by 800
Gris, D., Ye, Z., Iocca, H. A., Wen, H., Craven, R. R., Gris, P., Huang, M., Schneider, M., Miller, S. D., & Ting, J. P.-Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904145 · Cited by 429
How do immune cells overcome the blood-brain barrier in multiple sclerosis?
Larochelle, C., Alvarez, J. I., & Prat, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.066 · Cited by 405
“IL-17A and -17F protein and mRNA are elevated in PBMCs from clinically isolated syndrome (CIS) and in RRMS [44,92], especially during relapses [46,93].”
BackgroundIL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Metadata
- Authors
- Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B., Eid, P., & Novelli, F.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-05
- Volume
- 65
- Issue
- 5
- Pages
- 499-509
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2144013613
- Cited by
- 375
- References
- 42
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.